The organization warns of the risk of eye treatment at SUS

Age-related macular degeneration (AMD) could cause blindness. Photo: Vencer Limits weblog.

The NGO Retina Brazil expressed concern about the proposal to replace the Treatment protocol (PCDT) for age-related macular degeneration (AMD) which incorporates the drug bevacizumab in the treatment launched in Unified Health System (SUS) for sufferers over 60 years of age.

“Bevacizumab is a drug that isn’t accepted for ophthalmic use by Anvisa (National Health Surveillance Agency), however is however used to deal with moist AMD, and should be fractionated as a result of it’s in a 4ml ampoule. The PCDT informs about the chance of problems arising from the fractionation of the drug, regarding contamination or discount of its effectiveness after fractionation (web page 28 of the PCDT),” the NGO mentioned.

The protocol now recommends the use of ranibizumab and aflibercept. The establishment praised the proposal to broaden treatment, however famous the dangers and adversarial results for sufferers with bevacizumab fractionation.

“Although the PCDT concludes (web page 30) that the three medication are protected for the treatment of neovascular AMD, it additionally recommends that acceptable fractionation guidelines be adopted to take care of the drug composition,” says Retina Brasil.

“We have been more than happy to develop this PCDT involving sufferers in the treatment of this pathology that results in imaginative and prescient loss. This is a long-awaited measure. It is essential for SUS to deal with sufferers with neovascular AMD. The introduction of medicines in public well being care is crucial in order that there isn’t any inequality in treatment between the private and non-private sectors”, the organization provides.

On September 9, however the outcomes haven’t been printed but.

“Expectations are for an indication solely subsequent month, at a brand new Conitec assembly. Patients are ready for the end result to understand how the PCDT will likely be in order that the facilities can present the therapies”, commented Retina Brasil.

Questioned by weblog overcoming boundaries on the causes for the inclusion of bevacizumab in the treatment of AMD, the Ministry of Health responded in a observe.

“The Ministry of Health informs that the replace of the textual content has handed public session and can go to the remaining evaluation of the National Commission for the Implementation of Technologies in SUS (Conitec). The new textual content consists of the advice of bevacizumab for the treatment of the illness, a drug that was already beneficial in the model of the protocol printed in 2018. The authorization for the unique use of the drug for the treatment of the illness was given by the National Health Service Surveillance Agency (Anvisa). following an analysis demonstrating the efficacy and security of bevacizumab in the treatment of age-related macular degeneration (AMD)”the observe says.

Screenshot of a Retina Brasil Facebook post.  Click on the image to access the full post.

Click on the picture to learn the whole publish. Photo: Reproduction.

Leave a Reply

Your email address will not be published.